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Protective role of appendicectomy on onset and severity of ulcerative colitis and 
Crohn’s disease  
 
ABSTRACT 
Background and aims: Recent studies on appendicectomy rates in ulcerative colitis 
and Crohn’s disease have generally not addressed the effect of appendicectomy on 
disease characteristics. The aims of this study were to compare appendicectomy rates 
in Australian inflammatory bowel disease patients and matched controls, and to 
evaluate the effect of prior appendicectomy on disease characteristics.  
 
Methods: Patients were ascertained from the Brisbane Inflammatory Bowel Disease 
database. Controls matched for age and sex were randomly selected from the 
Australian Twin Registry. Disease characteristics included age at diagnosis, disease 
site, need for immunosuppression, and intestinal resection.  
 
Results: The study confirmed the significant negative association between 
appendicectomy and ulcerative colitis (odds ratio (OR) 0.23, 95% confidence interval 
(CI) 0.14–0.38; p<0.0001) and found a similar result for Crohn’s disease once the bias 
of appendicectomy at diagnosis was addressed (OR 0.34, 95% CI 0.23–0.51; 
p<0.0001). Prior appendicectomy delayed age of presentation for both diseases and 
was statistically significant for Crohn’s disease (p=0.02). In ulcerative colitis, patients 
with prior appendicectomy had clinically milder disease with reduced requirement for 
immunosuppression (OR 0.15, 95% CI 0.02–1.15; p=0.04) and proctocolectomy 
(p=0.02).  
 
Conclusions: Compared with patients without prior appendicectomy, appendicectomy 
before diagnosis delays disease onset in ulcerative colitis and Crohn’s disease and 













Protective role of appendicectomy on onset and severity of ulcerative colitis and 
Crohn’s disease  
 
Crohn’s disease (CD) and ulcerative colitis (UC) represent the most common forms of 
idiopathic inflammatory bowel disease (IBD), with a prevalence of 0.2–0.5% within 
Caucasian populations.1 Both diseases are associated with episodes of acute or 
chronic inflammation affecting either the large bowel alone (UC) or both the small 
and large bowel (CD).2 This intestinal inflammation is characterised by the presence 
of activated T and B lymphocytes and macrophages, and is thought to be an 
inappropriate response to local commensal bacteria.3 Both genetic and environmental 
factors play a role in determining this response and after extensive research the first 
IBD susceptibility gene, Nod2, has been identified on chromosome 16.4,5 Cigarette 
smoking remains the only environmental agent that has been confirmed as an 
independent risk factor.6 Smoking is positively associated with the development of 
CD and can make the disease worse. In contrast, there is a significant protective effect 
of smoking on UC and nicotine patches have been used effectively to treat mild UC.7  
 
More recently, there has been increasing interest in the role of the appendix on the 
development of IBD. There have now been 18 independent studies investigating this 
relationship of which 15 showed a highly significant negative association between 
appendicectomy and UC.8–25 Patients with CD were similarly assessed in 10 of 18 
studies, and although eight showed a positive association in only one study was this 
statistically significant.8 At least two studies, one of which included both incident and 
prevalent cases, indicated that a significantly larger proportion of appendicectomies in 
patients with CD had been performed close to the time of diagnosis of the 
disease.16,22 Two hypotheses have been generated from these studies which are not 
mutually exclusive. Firstly, patients who have an appendicectomy differ from those 
who develop UC in terms of genetic or environmental risk factors; and secondly, early 
appendicectomy modifies the intestinal immune response to protect against the 
development of UC. There is some support for the first hypothesis with a recent 
population based analysis indicating that only appendicectomy for inflammatory 
disorders (appendicitis or mesenteric adenitis) protects against the development of 
UC.21 This study also confirmed the relevance of age at appendicectomy, with those 
individuals who had undergone surgery before 20 years gaining protection, as initially 
suggested by Duggan and colleagues.17 However, there was no clear association 
between domestic hygiene, assessed by the prevalence of Helicobacter pylori serology 
and availability of hot running water, and the low rate of appendicectomy in UC 
patients.11,17  
 
Support for the second hypothesis comes from work on the T cell receptor  knockout 
murine model of colitis, where removal of the "caecal patch", considered to be 
equivalent to the human appendix, at 3–5 weeks of age suppressed the development of 
colitis.26 However, surgery at an older age (>6 weeks) was less effective. Similarly, 
appendicectomy, but not splenectomy, in a DSS murine model of colitis significantly 
reduced the severity of disease compared with sham operated and unoperated control 
animals.27 In these animal models there was no evidence of appendicitis prior to 
surgery.  
 
To extend the human studies, and specifically to investigate the clinical effects of 
early appendicectomy on patients with IBD, we have carried out a detailed analysis of 
appendicectomy in both UC and CD, using a large consecutive series of patients from 
two IBD centres and a large set of community based controls matched for age and 
sex, and who had previously reported on appendicectomy and smoking habits.28 We 
demonstrate a relationship between age at appendicectomy and IBD (for both UC and 
CD) and provide novel data on the role of appendicectomy in determining age of 





Patients in this study were recruited by the Brisbane Inflammatory Bowel Disease 
Research Group which has an extensive clinical database that is based at the two 
major IBD referral centres within Brisbane. For analysis in this study, there were 
complete and informative data on 307 UC patients and 335 Crohn’s patients. Those 
patients with a definite diagnosis of either UC or CD, based on standard clinical, 
radiological, and histological criteria as defined by Lennard-Jones,29 were 
consecutively entered onto a database between 1995 and 1999, after interview or after 
completing a detailed questionnaire. If the database entry or questionnaire was 
incomplete, the patient was contacted by telephone or seen in clinic to supply the 
missing information.  
 
Specific questions relating to appendicectomy, indication for surgery, and date of 
surgery were incorporated into the database and questionnaire. The date of surgery in 
relation to the date of diagnosis of IBD was carefully assessed in order to investigate 
the precise relationship between appendicectomy and the risk of IBD. Therefore, 
appendicectomy performed after the diagnosis of IBD was disregarded for the 
purposes of this study. All histology reports available on patients who had undergone 
appendicectomy prior to a clear diagnosis of IBD were retrieved from archives or 
from patient records, and the slides reviewed to exclude the presence of either colitic- 
or CD-type changes, and to confirm the diagnosis of appendicitis or a histologically 
normal specimen. In all of these cases, the histopathologist was blinded to the clinical 
data pertaining to each of these patients.  
 
Together with a history of all surgical episodes, the database recorded other 
phenotypic parameters including: date of diagnosis, site and distribution of disease, 
complications of IBD, disease activity (clinical, inflammatory indicators, pathological 
assessments), family history, radiological investigations, detailed smoking history, 
medications, and contact details, as well as appendicectomy, other surgery, and dates 
of surgery. The use of immunosuppressive therapy (defined as the use of azathioprine, 
6-mercaptopurine, methotrexate, or mycophenolate for a minimum of 12 months’ 
continuous treatment at standard recommended doses) to control disease activity, and 
all disease related surgical episodes were noted. Disease distribution for UC patients 
was simplified into two groups: those with disease limited to the left colon (up to the 
splenic flexure), including patients with ulcerative proctitis; and those with total or 
subtotal colitis (beyond the splenic flexure). Distribution was assessed 
macroscopically and microscopically at the time of diagnosis and at subsequent 
colonoscopies. The maximum extent recorded was used in the classification for this 
study, and the criterion for extent was based on histological (microscopic) 
distribution. CD patients were classified according to the distribution of their luminal 
disease apart from a small number of patients with pure perianal CD. The CD groups 
were as follows: ileal, ileocolonic, colonic, and pure perianal disease. These 
descriptors were based on colonoscopy, ileoscopy, histology, and small bowel 
contrast studies. Ethics approval was obtained from the respective hospitals’ ethics 
committees and written, informed consent was obtained from all patients for entry of 
data onto the database.  
 
Controls 
Controls were randomly selected from a twin database that contains 3808 twin pairs 
from around Australia enrolled with the Australian Twin Registry. During 1980–
1982, these twin pairs took part in a health survey by mailed questionnaire which 
included items on common operations, including appendicectomy, and lifestyle 
habits, including smoking.28 One twin from each pair was selected randomly as a 
control, and up to five of these controls were matched by sex and five year birth 
intervals to each IBD case.  
 
Statistical methods 
Smoking status was classified as never smoker, ex-smoker, or current smoker for 
patients and controls. Comparisons of categorical variables (such as smoking status 
and history of appendicectomy) between IBD cases and controls, and between cases 
with and without prior appendicectomy, were conducted using Pearson’s 2 statistic. 
Odds ratios (ORs), together with 95% confidence intervals (CIs), were calculated to 
estimate the relative risk of disease status associated with various exposures. Multiple 
logistic regression was used to remove the effect of potential confounding by age, sex, 
and smoking status on disease/exposure associations, with corresponding calculation 
of adjusted p values, ORs, and 95% CIs. Comparisons of continuous approximately 
normally distributed variables such as age at diagnosis and time between 
appendicectomy and diagnosis were made using t tests and analysis of variance 
(ANOVA). All analyses were performed using SAS for Windows Release 8.1 (Cary, 




Characteristics of patients and controls 
Patients with left sided UC (173 or 56.5%) outnumbered those with subtotal or total 
disease (133 or 43.5%). Overall, 60 (19.6%) UC patients required colectomy for 
control of severe or refractory disease and 72 (23.5%) required immunosuppression 
for the same indications. Six patients (2%) underwent colectomy for colorectal 
carcinoma or high grade dysplasia complicating their UC. There were more patients 
with ileal (37%) and ileocolonic Crohn’s disease (38%) compared with pure colonic 
(24%) and pure perianal disease (0.9%). We found that 43% of CD patients required 
immunosuppression and 60% required at least one intestinal resection.  
 
Smoking and IBD 
For UC, current smoking appeared to be protective (OR 0.1, 95% CI 0.1–0.2) but 
smoking prior to disease onset (ex-smokers) was positively related to disease (OR 2.7, 
95% CI 2.0–3.6) (table 1). The prevalence of never smokers was the same among UC 
cases (54%) and controls (53%). As expected, there was a positive association 
between smoking and CD, with current smokers being at a higher risk (OR 2.0, 95% 
CI 1.5–2.6) than ex-smokers (OR 1.1, 95% CI 0.7–1.6) (table 2). These results 
persisted after adjustment for age, sex, and appendicectomy.  
 
   Table 1 Appendicectomy rates in ulcerative colitis patients and matched controls   
  
 




Appendicectomy rate and IBD 
Among UC patients, the overall rate of prior appendicectomy was 6.8% compared 
with 23.1% in controls, with an OR corrected for age, sex, and smoking of 0.23 (95% 
CI 0.14–0.38; p<0.0001). This OR was even lower (0.16, 95% CI 0.08–0.32) among 
patients who had appendicectomy performed at or before the age of 20 years (table 1). 
Of all the CD patients, 65 had undergone appendicectomy at any time, of which 36 
had appendicectomy prior to the diagnosis of CD. Thus the prior appendicectomy rate 
for CD was 10.8% compared with 24.9% for age cohort controls, giving an adjusted 
OR of 0.34 (95% CI 0.23–0.51; p<0.0001). Once again, the OR was lower at 0.33 
(95% CI 0.2–0.53) for appendicectomy performed at or prior to 20 years of age (table 
2).  
Effect of prior appendicectomy on disease phenotype 
These data are consistent with a significant protective effect of appendicectomy on the 
incidence of both UC and CD. Therefore, we examined the relationship between 
appendicectomy and disease severity, which we postulated might be worse in IBD 
patients with their appendix in situ at the time of diagnosis (tables 3, 4). Severity was 
assessed by (i) age at diagnosis, (ii) extent of disease, and (iii) need for 
immunosuppressive therapy and/or need for intestinal resection in order to control the 
disease (excluding colectomy or other intestinal resection for cancer or high grade 
dysplastic lesions).  
 
 
   Table 3 Effect of appendicectomy on ulcerative colitis characteristics (n=307)   
  
 




Of 21 patients with UC who had an appendicectomy prior to their diagnosis, 20 had 
mild disease as defined by no requirement for immunosuppression or colectomy. 
These 20 patients were receiving no maintenance treatment (n=3), an oral 5-ASA 
agent alone (n=14), or both oral and intermittent rectal 5-ASA (n=3). Only one of 21 
(4.8%) patients has required ongoing immunosuppression compared with 71/286 
(25%) in the non-appendicectomy group (p=0.04). None of the 21 patients in the 
appendicectomy group underwent colectomy for clinically severe IBD compared with 
60/281 (21%) patients in the rest of the UC cohort (p=0.02). When combining these 
two groups, only 1/21 (4.8%) patients with a previous appendicectomy needed 
immunosuppression or colectomy compared with 106/281 (38%) in the rest of the 
cohort (OR 0.09, 95% CI 0.04–0.81; p=0.003). The one patient who has required 
ongoing immunosuppression for refractory UC in the appendicectomy group is 
Chinese, an ethnic group with a very low incidence of UC. Age at diagnosis tended to 
be later in those patients with prior appendicectomy (mean 38 years) compared with 
the rest of the cohort (mean 31 years) (p=0.08). The UC cases with prior 
appendicectomy were more likely to have subtotal or total colitis (13/21 (62%)) 
compared with 120/285 (42%) in non-appendicectomy UC patients (p=0.08).  
Effect of prior appendicectomy on CD phenotype 
Mean age at diagnosis in the 36 appendicectomy cases was greater (36 years) 
compared with the rest of the group (30 years) (p=0.02). This difference remained 
significant after adjustment for sex, age, and smoking. Disease distribution in CD did 
not differ significantly between those 36 patients with a definite prior appendicectomy 
and the rest of the CD group (n=299). Ileal cases included those with some 
inflammation in the adjacent caecum but no other colorectal disease. Similarly, 
disease behaviour, classified as stricturing, penetrating, or non-stricturing non-
penetrating,30 was not influenced by prior appendicectomy (p=0.7). Mean duration 
between appendicectomy and diagnosis of CD did not correlate with disease site 
(p=0.94). With respect to disease severity, use of immunosuppression was not 
significantly different between CD patients with appendicectomy (14/36, 39%) and 
those without appendicectomy (130/299, 43%). Rates of intestinal resection were also 
similar (177/299 or 59% in the non-appendicectomy group v 23/36 or 64% in the 
appendicectomy group).  
 
Histology of appendix in prior appendicectomy group 
Histology of the appendix was retrievable in 8/21 UC patients and in 8/36 CD patients 
who had undergone a prior appendicectomy, as the majority of the patients had 
undergone surgery before 1980 and their records had been destroyed. Of the 57 
patients in the appendicectomy group, only five (three CD, two UC) had undergone 
surgery within the two year period before their diagnosis. Histology was available on 
all of these patients and showed changes of typical mucosal appendicitis in all cases. 
Of the remaining 11 patients with available histological data, eight had definite 
mucosal appendicitis (four CD, four UC) and three had histologically normal 




The present large and well controlled study confirms the significant negative 
association between appendicectomy and UC and also for the first time suggests the 
same association in CD if the confounding factor of surgery related to the disease 
itself is taken into account. In addition, the study indicates that prior appendicectomy 
may be associated with older age at diagnosis for both UC and CD, and with a 
clinically less severe course in patients with UC compared with patients with their 
appendix in situ. Finally, it also supports the importance of age at appendicectomy in 
UC, with early appendicectomy (before 20 years) conferring more protection than 
appendicectomy at an older age.  
 
While our data in the UC population are comparable with those of the majority of 
other studies, with the statistical power in the current study being enhanced by large 
numbers of patients and controls, our CD data are not in agreement with these studies, 
which raises the possibility of a type I statistical error. Both the UC and CD groups 
were carefully collected, and the dates of previous surgery confirmed in all cases by 
direct patient interview and by referring to current or previous hospital records. We 
addressed the potential bias of appendicectomy in CD patients being directly related 
to the disease itself, and our values for UC patients (6.8%) and CD patients (10.8%) 
are both comparable with the respective incident values (6% for UC and 9% for CD) 
given by Russel and colleagues.16 The prevalence of appendicectomy in our control 
population was high compared with control appendicectomy rates in other studies. 
This is because of the inclusion of appropriately age matched controls, and reflects the 
high appendicectomy rates that used to pertain in Australia.28,31 The controls in the 
present study were all drawn from a large community based twin population which 
permits great confidence in the interpretation of our data. The twins had volunteered 
to help in the collection of research data with respect to health and lifestyle, but were 
not accessed in relation to specific "hospital or health clinic seeking behaviour". In 
comparison, the majority of the other studies have used either small numbers of 
controls, hospital controls, or controls obtained from a general practitioner list.16  
 
Data for smoking and UC are in agreement with previous studies. In particular, the 
increased risk of the disease in non-smokers is the result of a large number of former 
smokers.32,33 Data for smoking and CD suggest a stronger positive association 
between current smokers and the disease compared with ex-smokers in our cohort, 
which again is in agreement with the majority of previous studies.32,33 Adjustment 
for smoking status did not weaken the negative associations between either UC or CD 
and previous appendicectomy.  
 
Both the delay in disease presentation in IBD, which was evident for both UC and CD 
patients with prior appendicectomy, and the reduction in several disease severity 
parameters for patients with UC, are important novel observations. They are 
supported by the observations made in animal models of IBD.26,27 The results are 
also consistent with two previous studies that found that appendicectomy before age 
20 years confers protection against UC17,21 and with Naganuma et al who found that 
appendicectomy prior to a diagnosis of UC reduces relapse rate, as measured by the 
need for oral steroids.23  
 
The lower OR values for UC compared with CD and the results of other studies 
indicate that appendicectomy is more protective for UC than CD. Previous work has 
suggested that UC pathogenesis may be dominated by a humoral or B lymphocyte 
immune response whereas CD is dominated by a strong T lymphocyte response.34–37 
This, together with the above observations, suggests at least one hypothesis: the B 
lymphocyte component within the appendix may be necessary for seeding the 
immune system of the gut with IgA producing plasma cells. IgA (or IgM) produced 
by these cells has an important role in excluding bacteria. Aberrant immunoglobulin 
switching could result in pathological production of IgG which is not important for 
bacterial exclusion but by binding complement promotes a cellular immune 
response.38,39 If the appendix is removed early from a patient carrying the genetic 
susceptibility for developing UC (or CD), then this may be enough to either prevent 
or ameliorate the disease. On the other hand, although the disease may be milder, its 
extent may be increased because of diminished bacterial exclusion throughout the 
intestine. This hypothesis has indirect support from work on neonatal rabbits which 
shows diminished mucosal IgA, IgM, and IgG in the small bowel after early 
appendicectomy (levels were not reported for the colon).40  
 
The alternative but not mutually exclusive hypothesis is that it is the inflammation of 
appendicitis (and/or mesenteric adenitis) that is important in conferring protection 
against UC. Our histological data are consistent with this hypothesis but do not 
exclude a role for appendicectomy per se. Andersson et al, who provided supportive 
evidence for appendicitis or mesenteric adenitis being necessary for protection against 
UC, argued that this might be due to dominance of a Th1 cytokine profile in these 
patients compared with a Th2 cytokine profile associated with UC.21 However, 
appendicectomy was the sole end point for inclusion in their study and therefore 
removal of the appendix itself may also have been protective. Furthermore, the 
Andersson study may have failed to capture many UC patients who had a prior 
appendicectomy. This is because only patients with UC that required hospital 
admission for their UC disease were included in the Andersson study. Yet in our 
study we demonstrated that it was these same patients who had appendicectomy that 
had mild disease and therefore may never have required hospital admission. Further 
support for this is the low appendicectomy rate (0.9%) in our patients with refractory 
UC (requiring immunosuppression and/or colectomy) compared with the overall UC 
rate of 6.8%. These patients all required hospital admission for UC.  
 
In summary, our study strongly supports the negative age related association between 
prior appendicectomy and UC, and for the first time demonstrates a similar 
association for CD. Comparative analysis clearly shows that prior appendicectomy is 
associated with a more benign phenotype in UC, and a delay in onset of IBD. These 
results are consistent with the hypothesis that the appendix contributes to the 
development and maintenance of the gut immune system, as suggested in animal 
models, but does not exclude an inverse relationship between appendicitis (and/or 
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